

REMARKS

Further consideration of this application is requested. Claims 8-11 remain active in the application. Of these, claim 10 has been allowed while claims 8, 9 and 10 are rejected over U.S. patent 5,438,150 to Bansal et al. Claim 8 is amended to exclude the compound of Molloy by adding a further "proviso" excluding (f) R=R₁-F and R₂=H to claim 8.

Applicants submit that the claims of this application are now in condition for allowance and that claims 8, 9 and 11 should also be allowed with claim 10.

Favorable action is solicited.

Attached hereto is a marked-up version of the changes made to the claims by the current amendment. The attached page is captioned "Version With Markings To Show Changes Made."

Respectfully submitted,

NIXON & VANDERHYE P.C.

By:



Arthur R. Crawford
Reg. No. 25,327


ARC:

1100 North Glebe Road, 8th Floor
Arlington, VA 22201-4714
Telephone: (703) 816-4000
Facsimile: (703) 816-4100


VERSION WITH MARKINGS TO SHOW CHANGES MADE

IN THE CLAIMS

8. (Twice Amended) A 2-aminoteraline of the formula (I)



or a pharmacologically acceptable salt of the formula (II)



wherein:

R and R₁ are independently halogen, hydroxy, or C₁-C₄ alkoxy optionally substituted in position ω with a group selected from OH, NH₂ or NR₃R₄, wherein R₃ and R₄ are independently H, C₁-C₄ alkyl, unsubstituted or substituted in position ω with groups OH, NH₂, C₁-C₄ alkanoyl, C₁-C₄ alkyl, carbamoyl, carbamoyloxy, amino, or amino-substituted NR₃R₄, where R₃ and R₄ have the above meanings,

R₂ is hydrogen, halogen, hydroxy or methoxy,

with the proviso that the 2-aminotetraline excludes (a) R=R₁=CH₃O or OH, R₂=H, (b) R=F, R₁=CH₃O or OH, R₂=H, (c) R₁=-OCH₃, R=CH₃ and R₂=H, (d) R=R₁=R₂=CH₃O, [or](e) R=R₁=Cl and R₂=H, or (f) R=R₁-F and R₂=H,

and X⁻ is the monovalent anion of a pharmacologically acceptable acid.